Arkansas Attorney General Sues 22 Drug Companies Over Alleged 340B Discount Restrictions
核心洞察
Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts.
The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act.
Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act.
Arkansas Attorney General Tim Griffin announced Wednesday that his office is suing 22 entities—including 13 of the world's largest pharmaceutical manufacturers—accusing them of illegally restricting access to prescription drug discounts under the federal 340B program. The lawsuit, filed under Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act, marks a significant escalation in the state's years-long battle against what Griffin characterized as drug manufacturer pricing practices that prioritize "profits over patients."
Speaking at a press conference alongside healthcare professionals from UAMS, Mena Regional Health System, and other state institutions, Griffin named the defendants: Abbvie, Inc.; Amgen, Inc.; Amgen Manufacturing, Limited; Astrazeneca LP; Astrazeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Genzyme Corporation; Glaxosmithkline LLC; Immunex Corporation; Johnson and Johnson (搜索); Merck & Co. Inc.; Novartis AG; Novartis Pharmaceuticals Corporation; Novo Nordisk A/S; Novo Nordisk, Inc. (搜索); Pfizer, Inc.; Sanofi-Aventis U.S. LLC; Sanofi S.A. (搜索); Sanofi US Services Inc.; and Second Sight Solutions, LLC.
Legal Foundation and the 340B Program
Arkansas Act 1103 was enacted to protect pharmacies and their patients from unfair pricing practices and to improve healthcare access for uninsured patients by discounting drug prices. The 340B program requires pharmaceutical manufacturers to offer outpatient drugs at significantly reduced prices to eligible healthcare organizations—commonly referred to as covered entities—that serve vulnerable and underserved patient populations.
The Pharmaceutical Research and Manufacturers of America (搜索) (PhRMA), a trade group representing several of the major manufacturers named in the suit, including Johnson & Johnson and Pfizer, had previously challenged the Arkansas law as unconstitutional. However, in 2024, PhRMA lost that challenge in the U.S. Supreme Court, clearing the path for state-level enforcement.
Scope of Alleged Violations
Griffin stated that his office has identified approximately over 300,000 instances of conduct that violates the statute, and he indicated that the number is expected to grow. "Right now, we're talking about approximately over 300,000 instances of conduct that is volitive...we expect that there will be more beyond that 300,000," Griffin said.
The state is seeking civil penalties for each violation of the Arkansas Deceptive Trade Practices Act, along with injunctive relief that would prohibit the use of these restrictions within Arkansas. "The penalties are about making it so punitive that they never want to do this again in our state. They may want to try it somewhere else, but they shouldn't try it here," Griffin stated.
Impact on Healthcare Providers and Patients
John Vinson, CEO of the Arkansas Pharmacists Association, underscored the critical role the 340B program plays for healthcare providers across the state. "When those 340B savings are not available to these clinics and hospitals, then services are cut, and patients and communities lose access to critical care," Vinson said. He added, "There is an accountability to those laws being passed, and today that's what that's about."
The lawsuit represents one of the most comprehensive state-level enforcement actions targeting pharmaceutical manufacturers over 340B program compliance, and its outcome could have implications for how drug companies structure their discount programs nationwide.